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INTRODUCTION 
Adjuvant systemic chemotherapy is the standard treatment 
modality to improve the survival of breast cancer patients. 
Breast cancer is more responsive to the systemic chemotherapy 
than other solid tumors are [1,2]. Cyclophosphamide, metho-
trexate, and 5-fluorouracil (CMF) regimen, which was intro-
duced in the 1970s, is the most commonly used chemothera-
peutic regimen in breast cancer. CMF regimen has shown 
treatment associated survival benefit for over 40 years and it 
still is the standard chemotherapeutic regimen in breast cancer 
although the use of anthracycline and taxane based chemo-
therapy has been extended to early breast cancer [3,4]. 
However, in spite of its many merits as chemotherapeutic 
regimen, it frequently has been pointed out that cyclophos-
phamide, as an alkylating agent, induces permanent amenor-
rhea in premenopausal women who plan to have conception 
after treatment. In addition, methotrexate and 5-fluorouracil 
have the same anticancer mechanism as anti-metabolites [5-8]. 
Since 2000, we have administered cyclophosphamide, vinorel-
bine and 5-fluorouracil (CVF) instead of CMF regimen in 
early breast cancer patients because the authors considered 
that CVF regimen is more reasonable than the latter for early 
breast cancer considering the drug combination. Vinorelbine 
is frequently used in advanced breast cancer and has an ac-
ceptable overall response rate of about over 40% when used in 
first line [9-16]. Recently, one study group conducted a clin- 
ical trial with vinorelbine in early breast cancer patients with 
poor prognostic factors and they concluded that vinorelbine 
containing regimen provided a reliable efficacy [17].
The current study was performed to evaluate the feasibility 
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Purpose: Our study aimed to evaluate the feasibility of adjuvant 
cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy 
as an alternative to cyclophosphamide/methotrexate/5-fluoro-
uracil (CMF) chemotherapy for treating early breast cancer. 
Methods: One hundred and forty-nine patients were randomly 
assigned to CMF or CVF adjuvant chemotherapy for treating 
their early stage breast cancer between September 2000 and 
December 2007. The disease-free survival (DFS), the overall sur-
vival (OS), and the toxicity profiles of both groups were com-
pared. Results: Sixty-seven patients underwent CMF chemo-
therapy whereas 82 patients underwent CVF chemotherapy. The 
DFS and OS were 88 months (95% confidence interval [CI], 76-
101 months) and 94 months (95% CI, 83-104 months), respec-
tively for the CMF group, and 97 months (95% CI, 93-101 months), 
and 101 months (95% CI, 98-104 months), respectively for the 
CVF group. However, those survival gains of the CVF group were 
not statistically significant (p-value=0.069 for the DFS and 0.99 
for the OS). The CVF group showed a favorable toxicity profile in 
terms of the grade 3/4 hematologic toxicities as compared to that 
of the CMF group. Conclusion: Clinical outcome of CVF chemo-
therapy was comparable to CMF with a favorable toxicity pro-
files. However, it is difficult to conclude the feasibility of CVF reg-
imen because of small number of studied patients.
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of CVF regimen in early breast cancer when the disease-free 
survival and overall survival of CVF regimen are compared 
with those of CMF regimen.
METHODS
We randomly assigned 149 breast cancer patients to either 
CMF or CVF adjuvant chemotherapy after the breast surgery 
and axillary lymph node dissection (or sentinel lymph node 
biopsy) at Inje University Sanggye Paik Hospital. 
Patient selection
All patients were early breast cancer (stage I, II) patients with 
World Health Organization (WHO) performance status 0-2 
and have proper bone marrow, liver, and renal functions. The 
Institutional Review Board (99-32  ) approved the study.
All patients agreed on the informed consents and were pro-
vided with enough counseling for surgery and adjuvant sys-
temic chemotherapy. Patient with active infection, severe sys-
temic disease (i.e., uncontrolled diabetes, liver cirrhosis, con-
gestive heart failure, etc.), or serious psychiatric problem were 
excluded from the systemic adjuvant chemotherapy. 
Clinical and biological characteristics of the patients
Regarding the clinical stage, 52 (77.6%) were stage I and 15 
(22.4%) were stage II in the CMF group, and 43 (52.4%) were 
stage I and 39 (47.6%) were stage II in the CVF group (Table 
1). Although the latter had a slightly larger numbe r of stage II 
patients, there was no statistical difference between the two 
(p=0.052). Also the CVF group had a larger number of pa-
tients with a tumor size more than 2 cm (p=0.422) or lymph 
node metastasis (p=0.192), but they were also statistically not 
significant (Table 1). 
In comparison of the histological grade and the nuclear grade 
between the two groups, there was no statistical significance 
between the two groups. When the hormonal receptor status 
and the expression of HER2/neu were compared between the 
two groups, the CMF group had more patients with the two 
receptors and also HER2/neu expression, but there was no 
statistical significance (p=0.621). The CMF group had signifi-
cantly higher bcl-2 expression (p=0.026), whereas the Ki-67 
labeling index was not statistically significant
Adjuvant systemic chemotherapy
In control group, CMF regimen consisting of cyclophos-
phamide (600 mg/m
2 intravenously on day 1), methotrexate 
(40 mg/m
2 intravenously on day 1) and 5- fluorouracil (600 
mg/m
2 intravenously on day 1), was repeated every three weeks 
for six cycles. In the study group, six cycles of CVF regimen 
consisting of cyclophosphamide (600 mg/m
2 intravenously on 
day 1), vinorelbine (30 mg/m
2 intravenously on day 1) and 5- 
fluorouracil (600 mg/m
2 intravenously on day 1) was repeated 
Table 1. Clinical and pathologic characteristics of patients according to 
adjuvant chemotherapies
Adjuvant chemotherapy
Total 
(n=149)
p-value CMF (n=67), 
No. (%)
CVF (n=82),  
No. (%)
Age (yr)* 48.5 (23-71) 49.1 (31-66) 48.82
   <50 42 (62.7) 48 (58.5) 90 0.838
   ≥50 25 (37.3) 34 (41.5) 59 0.387
Stage 0.052
   I  52 (77.6) 43 (52.4) 95
   II 15 (22.4) 39 (47.6) 54
Tumor size (cm) 0.442
   ≤2 54 (80.6) 48 (58.5) 102
   >2, ≤5 12 (17.9) 31 (37.8) 43
   >5 1 (1.5) 3 (3.7) 4
Axillary LNs (No.) 0.192
   0 62 (92.5)  73 (89.0) 135
   1-3 5 (7.5) 9 (11.0) 14
HG  0.469
   1 10 (19.2) 13 (19.2) 23
   2 16 (30.8) 23 (33.8) 39
   3 26 (50.0) 32 (47.1) 58
NG 0.636
   1 23 (44.2) 30 (44.1) 53
   2 21 (40.4) 28 (41.2) 49
   3 8 (15.4) 9 (14.7) 28
ER 0.793
   Positive  62 (98.4) 71 (86.6)   133
   Negative 1 (1.6) 11 (13.4) 12
PgR 0.873
   Positive  62 (98.4) 69 (84.1) 131
   Negative 1 (1.6) 13 (15.9) 14
HER2/neu  0.621
   0 or 1+ 44 (69.9) 58 (74.4) 102
   2+ 19 (30.2) 16 (20.5) 35
   3+ 0 (0) 4 (5.1) 4
Ki67 (%) 0.822
   <15 27 (47.4) 27 (50.9) 61
   ≥15 32 (52.6) 26 (49.1) 58
Operation methods 0.271
   MRM 15 (22.4) 18 (22.0) 33
   BCS 52 (77.6) 64 (78.0) 116
Endocrine therapy  0.310
   Yes 53 (79.1) 67 (81.9) 120
   No 14 (20.9) 15 (18.3) 29
Radiation therapy 0.347
   Yes 47 (70.1) 50 (61.0) 97
   No 20 (29.9) 32 (39.0) 52
CMF=cyclophosphamide+methotrexate+5-fluorouracil; CVF=cyclophospha-
mide+vinorelbine+5-fluorouracil; LNs=lymph nodes; HG=histologic grade; 
NG=nuclear grade; ER=estrogen receptor; PgR=progesterone receptor; 
MRM=modified radical mastectomy; BCS=breast conserving surgery.
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every three weeks.
Blood samples of all patients were obtained on the fourteenth 
and 20th days after the start of chemotherapy for the surveil-
lance of toxicities and recovery from nadir. When the pretreat-
ment evaluations were acceptable to continue chemotherapy, 
the patients were administered for the next cycle of chemo-
therapy as scheduled. 
Radiation therapy
Locoregional radiation therapy after the surgery were con-
ducted in patients who received breast conserving surgery 
and in those who were confirmed to have axillary lymph node 
metastasis in the pathology report, axilla was included in the 
radiation field as well. Also in those who received modified 
radical mastectomy but whose pathology report showed pres-
ence of cancer cell in less than 1 mm from the deep margin or 
axillary lymph node metastasis, locoregional radiation treat-
ment was done. The entire breast parenchyma was included 
in the tangential field for radiation of 6MV X-ray and an ad-
ditional irradiation was done on the tumor bed. The mean ra-
diation dose was 56 Gy (range, 52-63 Gy) and the fractional 
dose was 56 Gy (range, 52-63 Gy). Each fraction dose was 1.8 
Gy and the mean number of fraction was 30 (range, 28-33), 
and it took 6-7 weeks in total [18]. 
Radiation therapy was conducted concomitantly with the 
chemotherapy. Post-operative hormone therapy was indicated 
in hormone receptor-positive patients and those whose recep-
tor status was not known. Anti-estrogen was the primary choice 
for the hormonal therapy and in post-menopausal patients 
with hypercholesterolemia, pulmonary embolism, or deep 
vein thrombosis, but without osteoporosis, aromatase-inhibi-
tors were considered secondarily. 
Statistics
For calculation of sample size, we expected the systemic re-
currence rate of both CVF and CMF chemotherapy as 10% 
(7-15%). The sample size was calculated on the basis of expect-
ed dropout rate of 10%. Around 95 subjects per each group 
were needed to evaluate the equivalent therapeutic efficacy of 
CVF chemotherapy to CMF chemotherapy.
Neutropenia, febrile neutropenia, anemia, thrombocytope-
nia, hepatotoxicity, and nephrotoxicity during the period of 
chemotherapy in the two groups were analyzed by Pearson’s 
chi-square test using SPSS software version 11.0 (SPSS Inc., 
Chicago, USA), and the p-value of less than or equal to 0.05 
was considered statistically significant.
Treatment results in each group according to the patient 
age, tumor size, number of lymph node metastases, stage, sur-
gical strategy, histologic grade, nuclear grade, estrogen recep-
tor, progesterone receptor, HER2/neu expression, Ki-67 label-
ing index, bcl-2 expression, hormonal therapy, and radiation 
therapy were evaluated by Cox regression analysis and the p-
value of less than or equal to 0.05 was considered statistically 
significant. 
RESULTS
Clinical characteristics of patients
Between September 2000 and December 2007, only 149 pa-
tients were enrolled to the study. The study was closed at De-
Figure 1. Disease-free survival curves of CVF (cyclophosphamide+ 
vinorelbine+5-fluorouracil) and CMF (cyclophosphamide+methotrexate+ 
5-fluorouracil) groups.
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Figure 2. Overall survival curves of CVF (cyclophosphamide+vinorelbine+ 
5-fluorouracil) and CMF (cyclophosphamide+methotrexate+5-fluoroura-
cil) groups.
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cember 2007 because of slow enrollment although the planned 
number of patients had not been enrolled.
Out of the 149 patients, 67 received CMF regimen and the 
remaining 82 received CVF regimen. The age range was 23-71 
(mean, 48.5) for the former and 31-66 (mean, 49.1) for the 
latter. The menopausal status of each patient was not recorded, 
but patients less than the age 50 were 42 (62.7%) in the CMF 
group and 48 (58.5%) in the CVF group. The number of pa-
tients aged more than 50 was 25 (37.3%) in the former and 34 
(41.5%) in the latter. The age (p=0.354) and the menopausal 
status (p=0.387) were not statistically significant between the 
two groups (Table 1).
The surgical methods in each group were 52 (77.6%) cases 
of breast conserving surgery and 15 (22.4%) cases of modified 
radical mastectomy in the CMF group, and 64 (78.%) cases of 
breast conserving surgery and 18 (22%) cases of modified rad-
ical mastectomy in the CVF group. There was no statistical 
difference between the two groups. Adjuvant hormonal ther- 
apy after the surgery and chemotherapy was administered in 
51 patients of CMF group and in 67 patients of CVF group. 
Locoregional radiation treatment was done in 47 of CMF group 
and in 50 of CVF group (Table 1). There was no statistical dif-
ference between the two groups regarding adjuvant hormonal 
therapy (p=0.310) and locoregional radiation (p=0.347).
Survival analysis
The median follow-up period was 59 months (range, 18-105 
months). In the CVF group, 5 patients had recurrent disease 
whereas 6 patients of the CMF group had recurrent disease. 
The disease-free survival rate was 93.9% for the former and 
91.0% for the latter (p=0.057) (Figure 1).
During the follow-up, 2 patients (2.4%) of CVF group died 
of recurrent breast cancer, whereas 3 patients (4.4%) of CMF 
group expired. There was no significant difference in overall 
survival of the patients between the two groups (p=0.155) 
(Figure 2).
Both disease-free survival and overall survival rates appeared 
to be lower in the CMF group compared with CVF group, but 
its statistical significance could not be verified due to the small 
number of patients. 
Chemotherapy related toxicity 
In evaluation of chemotoxicity, neutropenia in CMF group 
was observed in 152 cycles out of 403 cycles (37.7%), of which 
grade 3 or 4 neutropenia was in 20 cycles (4.9%). Similarly, 
neutropenia in CVF group was observed in 141 cycles out of 
381 cycles and grade 3 or 4 neutropenia was in 19 cycles (4.9%). 
There was no statistical difference between the two groups re-
garding neutropenia (p=0.762). Anemia was noted in 8 cycles 
in the CMF group and thrombocytopenia was not observed 
in both groups (Table 2). 
Liver enzyme level was abnormal in 118 out of 788 cycles 
and grade 3 or 4 hepatotoxicity was in 1 cycle in the CMF group 
and in 7 cycles in the CVF group. They were all grade 3 hepa-
totoxicity and all the patients recovered after chemotherapy. 
There was no statistical difference in terms of adverse effect 
from chemotherapy between the 2 groups (p=0.217). 
DISCUSSION
Systemic adjuvant chemotherapy is one of the standard 
treatment modalities for the breast cancer since the 1970s when 
Bonadonna et al. [5] started to use CMF regimen for the chemo- 
therapy of breast cancer. But from the 1990s, anthracycline 
and taxane became the key chemotherapeutic agents for the 
breast cancer because the results of large clinical trials showed 
additional survival benefits when compared with CMF [19,20]. 
Although anthracycline containing regimens have marginal 
superiority in terms of disease free and overall survival, sev- 
eral toxicities from anthracycline such as cardiotoxicity and 
alopecia are still the main obstacle to wide use of anthracycline 
regimens in adjuvant setting for early breast cancer. Alopecia 
is specifically a main complaint in Korean women with breast 
cancer. Many women hesitate to return to their social activity 
due to alopecia even after the completion of adjuvant chemo-
therapy. There was no grade 3 or 4 alopecia in both CMF and 
CVF group in the current study. Thus, the compliance to the 
CVF chemotherapy was good in studied patients.
Subset analysis of recent clinical trials has indicated that the 
benefit of anthracycline might confine to small subset of pa-
tients who harbor HER2 and/or topoisomerase2-alpha ampli-
Table 2. Chemotherapy induced toxicities in the patients received CMF 
or CVF regimen
Chemotherapeutic regimen
Total p-value
CMF No. (%) CVF No. (%)
Hematologic toxicities  0.762
   Neutropenia 152 (37.6) 141 (36.9) 293
   Febrile neutropenia 15 (3.7)   4 (1.0) 19
   Anemia    8 (1.9)   0 (0.0) 8
    thrombocytopenia   0 (0.0)   0 (0.0) 0
Liver toxicities 0.217
   AST/ALT elevation    60 (13.2)   48 (15.1) 108
   Total bilirubine elevation    2 (0.4)   6 (1.2) 8
   ALP elevation   0 (0.0)   0 (0.0) 0
   γ-GPT elevation   0 (0.0)   0 (0.0) 0
CMF=cyclophosphamide, methotrexate, 5-fluorouracil; CVF=cyclophospha- 
mide, vinorelbine, 5-fluorouracil; AST=aspartate transaminase; ALT=alanine 
transaminase; ALP=alkaline phosphatase; γ-GTP=gamma glutamyl trans-
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fication [21,22]. The results of those clinical trials suggest that 
the patients who do not have HER2 and/or topoisomerase2-
alpha amplification may not benefit from anthracycline con-
taining regimens. The results of recent clinical trials in terms 
of anthracycline sensitivity have to be verified by further study, 
since the meta-analysis of early breast cancer treatment trials 
consistently shows the increased survival benefit of anthracy-
cline containing regimens compared with CMF [23]. How- 
ever, obligatory use of anthracycline in early breast cancer needs 
to be reconsidered when we consider the increased incidence 
of adverse effects by anthracycline. That is a reason why we 
have designed the current study.
The authors speculated that since methotrexate and 5-fluo-
rouracil have the same anticancer mechanism, methotrexate 
can be substituted by another drug with different anticancer 
mechanism and the results would not be inferior. As afore-
mentioned, vinorelbine, a potent inhibitor of mitotic microtu-
bule polymerization and whose chemotherapeutic effect has 
been validated in progressive and metastatic breast cancer, 
started to be used in the place of methotrexate, an antimetab-
olite [9,15,16]. 
There was one study reporting the chemotherapeutic effect 
of vinorelbine combined with other drugs on progressive and 
recurrent breast cancer. Ardavanis et al. [24] reported com-
plete remission rate of 12%, partial remission rate of 38%, and 
overall response rate of 51% in metastatic, locally progressive, 
or recurrent breast cancer patients with CVF regimen. Recent-
ly, vinorelbine containing chemotherapeutic regimen has been 
tried in early breast cancers in clinical trials [25] and a French 
study has reported in a clinical trial that epirubicin and vinorel-
bine (EV) regimen is not inferior to 5-fluorouracil, epirubicin 
and cyclophosphamide (FEC) regimen in lymph node posi-
tive early breast cancer [17].
Our study, the first to use CVF regimen in stage I and II early 
breast cancer, showed an almost equal or slightly better results 
with respect to the disease-free survival and overall survival 
when compared to CMF regimen. The CVF regimen had no 
statistically significant difference to the CMF regimen with re-
spect to the bone marrow toxicity or hepatotoxicity. Thus, 
CVF regimen is expected to be the reasonable effective substi-
tute for the CMF regimen in early breast cancer. 
In conclusion, CVF regimen, when compared to the CMF 
regimen, seems to be a safe and effective chemotherapeutic 
regimen in early breast cancer with comparable outcomes to 
CMF. However, our study was limited by small number pa-
tients. Prospective clinical study with a larger number of pa-
tients is necessary to verify the efficacy of CVF regimen as an 
adjuvant chemotherapeutic agent in early breast cancer. 
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